Abstract
Acute Myeloid Leukemia (AML) comprises a heterogeneous group of disorders, whose pathophysiology relies on abnormalities in genes related to cell commitment, proliferation and apoptosis. The characterization of such abnormalities allowed the identification of prognostic markers, which in addition to guide the choice for risk-adapted therapy, also became targets for drug development. Howev…